Bio-Rad Laboratories, Inc. $BIO Shares Bought by Franklin Resources Inc.

Franklin Resources Inc. increased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 15.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 131,705 shares of the medical research company’s stock after acquiring an additional 17,999 shares during the quarter. Franklin Resources Inc. owned approximately 0.49% of Bio-Rad Laboratories worth $31,783,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of BIO. Caitong International Asset Management Co. Ltd raised its position in shares of Bio-Rad Laboratories by 3,633.3% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 109 shares in the last quarter. Quarry LP bought a new stake in shares of Bio-Rad Laboratories in the first quarter worth $29,000. UMB Bank n.a. raised its holdings in Bio-Rad Laboratories by 89.8% in the second quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock valued at $40,000 after acquiring an additional 79 shares in the last quarter. Headlands Technologies LLC boosted its stake in Bio-Rad Laboratories by 64.1% during the 1st quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock valued at $87,000 after acquiring an additional 139 shares during the last quarter. Finally, Twin Tree Management LP bought a new position in Bio-Rad Laboratories during the 1st quarter valued at $87,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, November 22nd. Royal Bank Of Canada raised their price target on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Tuesday. Finally, Wells Fargo & Company increased their price objective on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Hold” and an average price target of $358.50.

Bio-Rad Laboratories Trading Down 1.6%

Shares of BIO stock opened at $326.95 on Thursday. Bio-Rad Laboratories, Inc. has a 1 year low of $211.43 and a 1 year high of $373.69. The firm has a market capitalization of $8.82 billion, a PE ratio of -13.45 and a beta of 1.04. The stock has a fifty day moving average of $307.49 and a two-hundred day moving average of $274.39. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.67 and a current ratio of 5.12.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Wednesday, October 29th. The medical research company reported $2.26 earnings per share for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). The company had revenue of $653.00 million for the quarter, compared to the consensus estimate of $651.30 million. Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.18%. Bio-Rad Laboratories’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.01 earnings per share. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Insider Activity at Bio-Rad Laboratories

In other news, EVP James Barry sold 700 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $306.18, for a total value of $214,326.00. Following the completion of the sale, the executive vice president directly owned 510 shares of the company’s stock, valued at approximately $156,151.80. This represents a 57.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 17.83% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.